Promising drug may slow blindness in teens with rare eye disease
NCT ID NCT05244304
First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times
Summary
This study tested an experimental drug called tinlarebant in 104 teenagers with Stargardt disease, a genetic condition that causes progressive vision loss. The goal was to see if the drug could slow the growth of damage in the back of the eye. Participants took the drug or a placebo daily for a set period, and researchers measured changes in eye scans and vision tests.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STARGARDT DISEASE 1 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Belite Study Site
Palo Alto, California, 94303, United States
-
Belite Study Site
Minneapolis, Minnesota, 55435, United States
-
Belite Study Site
Salt Lake City, Utah, 84132, United States
-
Belite Study Site
Westmead, New South Wales, Australia
-
Belite Study Site
East Melbourne, Victoria, Australia
-
Belite Study Site
South Brisbane, Australia
-
Belite Study Site
Ghent, Belgium
-
Belite Study Site
Beijing, China
-
Belite Study Site
Shanghai, China
-
Belite Study Site
Paris, France
-
Belite Study Site
Bonn, Germany
-
Belite Study Site
Tübingen, Germany
-
Belite Study Site
Kowloon, Hong Kong
-
Belite Study Site
Nijmegen, Netherlands
-
Belite Study Site
Basel, Switzerland
-
Belite Study Site
Taipei, Taiwan
-
Belite Study Site
Taoyuan City, Taiwan
-
Belite Study Site
London, United Kingdom
-
Belite Study Site
Southampton, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.